Clinical trial
Lucentis (Ranibizumab) for Eales' Disease
NCT00384449 · Oregon Health and Science University, Other · Completed
Key facts
| NCT number | NCT00384449 |
|---|---|
| Title | Lucentis (Ranibizumab) for Eales' Disease |
| Official title | The Use of a VEGF Inhibitor (Lucentis) in Refractory Macular Edema Due to Eales' Disease |
| Lead sponsor | Oregon Health and Science University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Eales' Disease |
| Intervention type | Drug |
| Interventions | Ranibizumab |
| Enrollment | 1 |
| Start date | Oct 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Oct 6, 2006 |
| Last update posted | Jun 11, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: